RUBY-4 is a phase 1b/2 clinical study for patients whose autoimmune cytopenia is not well controlled with their current medication(s). RUBY-4 is exploring the safety and potential effectiveness of an investigational drug called povetacicept (ALPN-303) for people with ITP, wAIHA, or CAD.
All participants who enroll in RUBY-4 will receive treatment with povetacicept given as an injection under the skin. There is no placebo group in RUBY-4.
PHASE 1b/2
Participants must meet the following requirements:
Additional requirements apply. Our study doctors can help determine if you qualify.
PHASE 1b/2
Participants must meet the following requirements:
Additional requirements apply. Our study doctors can help determine if you qualify.
PHASE 1b/2
Participants must meet the following requirements:
Additional requirements apply. Our study doctors can help determine if you qualify.
Povetacicept (pō-və-tak’-i-sept) is designed to block two molecules, BAFF (also called BLyS) and APRIL, that are important for the function and survival of cells that produce harmful antibodies in patients with ITP, wAIHA, and CAD.
In patients with ITP, these antibodies can cause inflammation and destroy platelets resulting in excessive bruising and bleeding. By blocking both BAFF and APRIL, povetacicept has the potential to prevent and/or reduce damage to platelets.
In patients with wAIHA and CAD, these antibodies can cause inflammation and destroy red blood cells, resulting in anemia with symptoms such as tiredness, weakness, and/or shortness of breath. By blocking both BAFF and APRIL, povetacicept has the potential to prevent and/or reduce damage to red blood cells.
A clinical study is a type of research using human volunteers. Doctors and scientists conduct clinical studies to find better ways to treat diseases and medical conditions. Each clinical study of an investigational medication like povetacicept is designed to help answer specific questions, such as whether it works and if it is safe. Before a new drug can be authorized and prescribed for a specific condition, it must be evaluated in clinical studies to make sure it is safe and effective.
Participation in a clinical study may provide the opportunity to receive novel treatments, expert care, and additional monitoring from medical staff. It can also offer hope for patients while helping advance science and contributing new knowledge about their disease, which may benefit others in the future.
© 2024 RUBY-4 Clinical Study. All Rights Reserved, Alpine Immune Sciences
